Compare Amphastar Pharmaceuticals Inc (AMPH) vs InMode Ltd (INMD) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

InMode (INMD) trades at $15.31, up 1.26% with a bullish technical outlook. The stock shows strong profitability with 76.52% gross margins and 20.69% net income margin, though 2026 earnings guidance suggests margin compression. Recent developments include an unsolicited acquisition offer from Steel Partners at $16.75 per share and ongoing shareholder activism. Technical indicators show bullish moving averages with neutral oscillators, while analyst consensus is divided between Buy and Hold ratings.

The investment case balances attractive valuation metrics (P/E 12.55, EV/EBITDA 5.39) against execution risks and shareholder disputes. Near-term catalysts include the Q3 2026 earnings report and potential acquisition developments. Key risks involve competitive pressures in medical aesthetics and ongoing securities investigations that could impact investor confidence.